Literature DB >> 2496962

Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test.

L L Levitsky1, D A Schoeller, G H Lambert, D V Edidin.   

Abstract

In 6 growth hormone-deficient children, we have demonstrated that 3-N-demethylation of caffeine as measured by the 13CO2 caffeine breath test is decreased following 1 month of growth hormone therapy (8.4 +/- 1.0 vs. 6.8 +/- 1.2% 13C/2 h after treatment). These findings could be of clinical importance. The initiation of growth hormone therapy in growth hormone-deficient children could alter the clearance of drugs metabolized through the mixed-function oxidase pathway given for concurrent conditions, and necessitate adjustment of the therapeutic regimen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496962

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  14 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

2.  Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.

Authors:  Nuntiya Somparn; Upa Kukongviriyapan; Wichittra Tassaneeyakul; Arunee Jetsrisuparb; Veerapol Kukongviriyapan
Journal:  Eur J Clin Pharmacol       Date:  2006-11-21       Impact factor: 2.953

Review 3.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

4.  Enhanced drug metabolism in young children with cystic fibrosis.

Authors:  A C Parker; P Pritchard; T Preston; R L Smyth; I Choonara
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

5.  A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.

Authors:  Farzaneh Salem; Trevor N Johnson; Khaled Abduljalil; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 6.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

7.  Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test.

Authors:  A C Parker; P Pritchard; T Preston; I Choonara
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

8.  Regulatory mechanisms of growth hormone secretion are sexually dimorphic.

Authors:  C A Jaffe; B Ocampo-Lim; W Guo; K Krueger; I Sugahara; R DeMott-Friberg; M Bermann; A L Barkan
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 9.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

10.  Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children.

Authors:  Blanca Sinués; Esteban Mayayo; Ana Fanlo; Esteban Mayayo; María L Bernal; Pilar Bocos; Elena Bello; Jose I Labarta; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2004-09-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.